SDC1 and cancer: The eradication of CD138+ clones can be achieved by direct/indirect mechanisms elicited by mAbs (VIS832), ADCs (indatuximab ravtansine) and other immunoconjugates (B-B4-I131), or by activating CD138-specific T cells to elicit strong cytotoxic effects against malignant cells, as is the case of PVX-410 cancer vaccine and CART-138 cells (see below).